A clinical trial comparing Lanconone® with ibuprofen for rapid relief in acute joint pain

Robert N Girandola, Shalini Srivastava, Costas C Loullis, Robert N Girandola, Shalini Srivastava, Costas C Loullis

Abstract

Background: To study the effect of Lanconone® (1000 mg) on acute pain on exertion as compared to the standard of care, Ibuprofen (400 mg).

Method: The study recruited 72 subjects diagnosed with mild to moderate knee joint pain on exertion. Subjects with Pain Visual Analogue Scale of more than 40 mm were included. Uphill walking was provided as the stressor using Naughton's protocol on a treadmill. The subjects walked for 10 minutes continuously followed by a rest period and baseline pain score for index knee joint was recorded. Subjects were administered a single dose of Lanconone® (1000 mg)/Ibuprofen (400 mg). Thereafter the same stressor was provided at 0.5, 1, 2, 3, 4, and 6 hours, subsequently, pain scores were recorded on a visual analogue scale. Double stopwatch method was used to evaluate the onset of pain relief and time taken to meaningful pain relief.

Result: Both Lanconone® and Ibuprofen showed the first perceived pain relief at 65.31 ± 35.57 mins as compared to 60.82 ± 32.56 mins respectively. The mean time taken to experience meaningful pain relief in Lanconone® group was 196.59 ± 70.85 mins compared to 167.13 ± 71.41 mins amongst Ibuprofen group. The meaningful pain relief continued for 6 hours.

Conclusion: The current study successfully demonstrated rapid pain-relieving potential of Lanconone® which was comparable to Ibuprofen. No adverse event related to the interventions was reported in the study.

Trial registration: Clinical trials.gov NCT02417506 . 21 January 2015.

Keywords: Analgesic; Arthritis; Glucosamine; Health supplement; Ibuprofen; Joint pain; Nonsteroidal anti-inflammatory drug; Rapid pain relief; Trauma; Visual analogue scale.

Figures

Fig. 1
Fig. 1
Participant flow in the study
Fig. 2
Fig. 2
Pain reduction with single dose of Lanconone® versus ibuprofen over 6 hours. VAS visual analog scale
Fig. 3
Fig. 3
Distribution of responders across the Lanconone® and ibuprofen groups

References

    1. Hoy DG, Smith E, Cross M, et al The global burden of musculoskeletal conditions for 2010: an overview of methods. Ann Rheum Dis. 2014;73(6):982-9. .
    1. Barbour KE, Helmick CG, Theis KA, Murphy LB, Hootman JM, Brady TJ, et al. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2010–2012. Morb Mortal Wkly Rep. 2013;62(44):869–73.
    1. Enohumah KO, Imarengiaye CO. Pain in osteoarthritis. Afr J Biomed Res. 2008;11(2):119–28.
    1. Zedde P, Mela F, Del Prete F, Masia F, Manunta AF. Meniscal injuries in basketball players. Joints. 2014;2(4):192–196.
    1. Mithoefer K, Peterson L, Zenobi-Wong M, Mandelbaum BR. Cartilage issues in football—today’s problems and tomorrow’s solutions. Br J Sports Med. 2015;49:590–6. doi: 10.1136/bjsports-2015-094772.
    1. Murray IR, Benke MT, Mandelbaum BR. Management of knee articular cartilage injuries in athletes: chondroprotection, chondrofacilitation, and resurfacing. Knee Surg Sports Traumatol Arthrosc. 2015: pp 1-10.
    1. Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Health Patient Saf. 2015;7:31–41. doi: 10.2147/DHPS.S71976.
    1. Olsen AM, Fosbøl EL, Lindhardsen J, Andersson C, Folke F, Nielsen MB, Køber L,Hansen PR, Torp-Pedersen C, Gislason GH. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients—a nationwide study. PLoS One. 2013;8(1):e54309.
    1. Mercer SW, Payne RA, Nicholl B, Morrison J. Risk of intracranial haemorrhage linked to co-treatment with antidepressants and NSAIDs. Biomed J. 2015;351:h3745.
    1. MacDonald TM, Richard D, Lheritier K, Krammer G. The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. Int J Clin Pract. 2010;64(6):746–55. doi: 10.1111/j.1742-1241.2010.02346.x.
    1. Kulkarni MP, Shakeel A, Shinde BS, Rosenbloom RA. Efficacy and safety of E-OA-07 in moderate to severe symptoms of osteoarthritis: a double-blind randomized placebo-controlled study. Am J Ther. 2011;18(2):170–7. doi: 10.1097/MJT.0b013e318209df49.
    1. Altman R, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039. doi: 10.1002/art.1780290816.
    1. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494–502. doi: 10.1136/ard.16.4.494.
    1. Symmons D, Mathers C, Pfleger B. Global burden of osteoarthritis in the year 2000. Geneva: World Health Organization; 2003.
    1. Kellgren-Lawrence classification: knee osteoarthritis classification and treatment options; 2011. . Accessed 18 Sep 2012.
    1. Marian A, Minor PT. Phd exercise in the treatment of osteoarthritis. Rheum Dis Clin North Am. 1999;25(2):397–415. doi: 10.1016/S0889-857X(05)70075-2.
    1. Mangione KK, Axen K, Haas F. Mechanical unweighting effects on treadmill exercise and pain in elderly people with osteoarthritis of the knee. Phys Ther. 1996;76:387–94.
    1. Gould D, et al. Visual analogue scale (VAS) J Clin Nurs. 2001;10:697–706. doi: 10.1046/j.1365-2702.2001.00525.x.
    1. Mc Cormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med. 1988;18:1007–19. doi: 10.1017/S0033291700009934.
    1. Wininger SJ, Miller H, Minkowitz HS, Royal MA, Ang RY, Breitmeyer JB, Singla NK. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery. Clin Ther. 2010;32(14):2348–69. doi: 10.1016/j.clinthera.2010.12.011.
    1. U.S. Food and Drug Administration. 2005 Public Health Advisory – FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). . (Accessed on January 11, 2013).
    1. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833e40.
    1. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. J Rheumatol. 1992;19(12):1950–4.
    1. Creamer P, Lethbridge-Cejku M, Hochberg MC. Determinants of pain severity in knee osteoarthritis: effect of demographic and psychosocial variables using 3 pain measures. J Rheumatol. 1999;26(8):1785–92.
    1. Miller G. Studying the difference between “statistical” and “clinically meaningful”. Pain Med News. 2010;8(9). .
    1. Cepeda MS, Africano JM, Polo R, Alcala R, Carr DB. What decline in pain intensity is meaningful to patients with acute pain? Pain. 2003;105(1–2):151–7. doi: 10.1016/S0304-3959(03)00176-3.
    1. Mona Abdel-Tawab, Oliver Werz and Manfred Schubert-Zsilavecz. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinetics 2011;50(6):349-69.
    1. Arendt-Nielsen L, Eskehave TN, Egsgaard LL, Petersen KK, Graven-Nielsen T, Hoeck HC, Simonsen O, Siebuhr AS, Karsdal M, Bay-Jensen AC. Association between experimental pain biomarkers and serologic markers in patients with different degrees of painful knee osteoarthritis. Arthritis Rheumatol. 2014;66(12):3317–26.
    1. Sharma JN, Sharma JN. Comparison of the anti-inflammatory activity of Commiphora mukul (an indigenous drug) with those of phenylbutazone and ibuprofen in experimental arthritis induced by mycobacterial adjuvant. Arzneimittelforschung. 1977;27(7):1455–7.
    1. Wilson PB. Ginger (Zingiber officinale) as an analgesic and ergogenic aid in sport: a systemic review. J Strength Cond Res. 2015;29(10):2980-95.
    1. Srivastava P, Shanker K. Pluchea lanceolata (Rasana): chemical and biological potential of Rasayana herb used in traditional system of medicine. Fitoterapia. 2012;83(8):1371-85.
    1. Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis: Cochrane Database Syst Rev. 2014 May 22;5:CD002947.
    1. Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR, Hooper MM, Bradley JD, Bingham CO, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795–808.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다